QUOTE AND NEWS
Motley Fool  Jul 24  Comment 
Ariad Pharmaceuticals sales are climbing, but its shares may not be a bargain.
MedPage Today  Jul 22  Comment 
(MedPage Today) -- Acceptable ARIA levels, but lack of cognitive improvements.
newratings.com  Jun 10  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) and Paladin Labs Inc., an operating company of Endo International plc (ENDP, ENL.TO), announced that ARIAD has granted Paladin exclusive rights to distribute Iclusig (as ponatinib...
Benzinga  Jun 3  Comment 
In a report published Wednesday, H.C. Wainwright analyst Reni Benjamin said that this year’s American Association of Clinical Oncology (ASCO) conference, which was held in Chicago from May 29 to June 2, comprised of presentations that...
newratings.com  May 31  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals, Inc. (ARIA) reported long-term follow-up data from the Phase 1 trial of Iclusig (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid...
Market Intelligence Center  May 5  Comment 
Ariad Pharmaceuticals (ARIA) traded between $9.10 and $9.45 before closing at $9.24 Monday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s algorithms have picked a Nov. '15 $8.00 covered call for a net...
FierceBiotech  Apr 29  Comment 
Activist investor Alex Denner has called off his proxy fight with Ariad Pharmaceuticals, a cease-fire that appears to have cost Harvey Berger, the biotech's founder and CEO, his job.
Market Intelligence Center  Apr 21  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on Ariad Pharmaceuticals (ARIA) could yield about 14.01% (19.01% annualized, for comparison purposes only) in 269 days. Pair a long position in the stock with the Jan....




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki